Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

被引：0
|
作者：
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
机构：
[1] Massachusetts General Hospital and Harvard Medical School,Translational Discovery & Development
[2] Moffitt Cancer Center-McKinley Outpatient Clinic,undefined
[3] Mayo Clinic,undefined
[4] Sarah Cannon Research Institute/Tennessee Oncology,undefined
[5] Icahn School of Medicine at Mount Sinai,undefined
[6] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[7] Florida Cancer Specialists-South/Sarah Cannon Research Institute,undefined
[8] GSK,undefined
[9] Ludwig Center at Harvard,undefined
[10] EQRx,undefined
[11] Boston Pharmaceuticals,undefined
[12] Alkermes Incorporated,undefined
[13] Bicycle Therapeutics,undefined
来源：
Nature Cancer | 2022年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1138 / 1138
相关论文
共 50 条
  • [41] A real-world evidence study of BRCA mutations and survival in HER2-negative breast cancer
    Dalvi, Tapashi
    McLaurin, Kimmie
    Briceno, Josefa
    Nordstrom, Beth
    Bennett, James
    Hettle, Robert
    Murphy, Brian
    Collins, Jenna
    McCutcheon, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 72 - 72
  • [42] Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
    Caramelo, Olga
    Silva, Cristina
    Caramelo, Francisco
    Frutuoso, Cristina
    Pinto, Leonor
    Almeida-Santos, Teresa
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2022, 20 (01)
  • [43] Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
    Olga Caramelo
    Cristina Silva
    Francisco Caramelo
    Cristina Frutuoso
    Leonor Pinto
    Teresa Almeida-Santos
    Hereditary Cancer in Clinical Practice, 20
  • [44] A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
    Nguyen, Vina P.
    Campbell, Katie M.
    Nowicki, Theodore S.
    Elumalai, Nila
    Medina, Egmidio
    Baselga-Carretero, Ignacio
    DiNome, Maggie L.
    Chang, Helena R.
    Oseguera, Denise K.
    Ribas, Antoni
    Glaspy, John A.
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1628 - 1637
  • [45] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [46] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
    Xu, Binghe
    Sun, Tao
    Shi, Yanxia
    Cui, Jiuwei
    Yin, Yongmei
    Ouyang, Quchang
    Liu, Qiang
    Zhang, Qingyuan
    Chen, Yiding
    Wang, Shouman
    Wang, Xiaojia
    Tong, Zhongsheng
    Zhong, Yahua
    Wang, Jiayu
    Yan, Min
    Yan, Xi
    Wang, Chuan
    Feng, Jifeng
    Wang, Xiuli
    Hu, Gang
    Cheng, Ying
    Ge, Ruimin
    Zhu, Zhaoyin
    Zhang, Wa
    Shao, Zhimin
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 197 (3) : 489 - 501
  • [47] Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
    Lucas, Mairi W.
    Kelly, Catherine M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2493 - 2506
  • [48] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
    Binghe Xu
    Tao Sun
    Yanxia Shi
    Jiuwei Cui
    Yongmei Yin
    Quchang Ouyang
    Qiang Liu
    Qingyuan Zhang
    Yiding Chen
    Shouman Wang
    Xiaojia Wang
    Zhongsheng Tong
    Yahua Zhong
    Jiayu Wang
    Min Yan
    Xi Yan
    Chuan Wang
    Jifeng Feng
    Xiuli Wang
    Gang Hu
    Ying Cheng
    Ruimin Ge
    Zhaoyin Zhu
    Wa Zhang
    Zhimin Shao
    Breast Cancer Research and Treatment, 2023, 197 : 489 - 501
  • [49] Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
    Ishikawa, Takashi
    Akazawa, Kouhei
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Hayashi, Mitsuhiro
    Kohno, Norio
    JOURNAL OF SURGICAL RESEARCH, 2017, 220 : 46 - 51
  • [50] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
12345